176 related articles for article (PubMed ID: 15888284)
21. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
22. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
[TBL] [Abstract][Full Text] [Related]
23. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
24. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
25. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies.
Louhimo J; Finne P; Alfthan H; Stenman UH; Haglund C
Anticancer Res; 2002; 22(3):1759-64. PubMed ID: 12168865
[TBL] [Abstract][Full Text] [Related]
26. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
27. [The significance of urine di-acetyl spermine level as a cancer marker for colorectal cancer].
Takahashi K; Hiramatsu K; Kawakita M; Mori T; Yamaguchi T; Matsumoto H; Miyamoto H; Tamamori Y
Rinsho Byori; 2004 Apr; 52(4):332-5. PubMed ID: 15164601
[TBL] [Abstract][Full Text] [Related]
28. Identifying markers for pancreatic cancer by gene expression analysis.
Zhou W; Sokoll LJ; Bruzek DJ; Zhang L; Velculescu VE; Goldin SB; Hruban RH; Kern SE; Hamilton SR; Chan DW; Vogelstein B; Kinzler KW
Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):109-12. PubMed ID: 9488584
[TBL] [Abstract][Full Text] [Related]
29. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
30. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
[TBL] [Abstract][Full Text] [Related]
31. [Factors affecting the increase of urinary diacetylspermine levels : a study in patients with liver diseases].
Enjoji M; Kotoh K; Nakamuta M;
Rinsho Byori; 2006 Feb; 54(2):126-31. PubMed ID: 16548232
[TBL] [Abstract][Full Text] [Related]
32. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
Szajda SD; Snarska J; Jankowska A; Roszkowska-Jakimiec W; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(82-83):388-93. PubMed ID: 18613372
[TBL] [Abstract][Full Text] [Related]
33. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
Ozkan H; Akar T; Köklü S; Coban S
Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598
[TBL] [Abstract][Full Text] [Related]
34. Diacetylated derivatives of spermine and spermidine as novel promising tumor markers.
Kawakita M; Hiramatsu K
J Biochem; 2006 Mar; 139(3):315-22. PubMed ID: 16567395
[TBL] [Abstract][Full Text] [Related]
35. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases.
Ozkan H; Demirbaş S; Ibiş M; Akbal E; Köklü S
Pancreatology; 2011; 11(3):295-300. PubMed ID: 21757969
[TBL] [Abstract][Full Text] [Related]
37. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
38. [Establishment of an ELISA system of N1,N12-diacetylspermine in human urine].
Matsuoka A; Sakamoto T
Rinsho Byori; 2004 Apr; 52(4):328-31. PubMed ID: 15164600
[TBL] [Abstract][Full Text] [Related]
39. Atypical courses of serum tumor markers--4 case reports.
Klapdor R; Bahlo M; Babinski A
Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
[TBL] [Abstract][Full Text] [Related]
40. [Urinary diacetylspermine: its analysis and performance as a novel tumor marker].
Kawakita M; Hiramatsu K; Takahashi K; Yamada R; Kawaguchi M; Shinoura N; Tanaka T; Kariyone K; Tamamori Y; Sasaki Y; Mori T
Rinsho Byori; 2005 Feb; 53(2):123-9. PubMed ID: 15796045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
